Nux Vomica 30x

Dosage for Strychnos Nux-vomica Seed is highly specialized and depends entirely on the clinical application:

• Allergenic Testing: Typically administered as a single drop (concentration varies by manufacturer, e.g., 1:10 or 1:20 w/v) for skin prick testing.
• Immunotherapy: Dosing follows a "build-up" schedule starting with extremely low concentrations (e.g., 0.01 mL of a 1:100,000 dilution) and increasing gradually under medical supervision.

Strychnos Nux-vomica Seed extracts are generally not recommended for use in children unless specifically directed by a pediatric allergist. The risk of systemic toxicity and the sensitivity of the pediatric immune system require extreme caution.

Renal Impairment

Because the alkaloids are partially cleared by the kidneys, patients with severe renal impairment (CrCl < 30 mL/min) should be monitored closely for signs of systemic toxicity if any significant absorption occurs.

Hepatic Impairment

Patients with hepatic cirrhosis may have reduced clearance of nux-vomica alkaloids, increasing the risk of CNS excitation. Dosage should be approached with extreme caution.

Elderly Patients

Elderly patients may have increased sensitivity to the CNS effects of strychnine. Clinical monitoring for muscle stiffness or hyperreflexia is recommended during immunotherapy.

This substance should never be self-administered in its raw or extract form.

• Clinical Setting: Must be administered in a facility equipped to handle anaphylaxis.
• Storage: Store at 2°C to 8°C (36°F to 46°F). Do not freeze.
• Administration: For skin testing, the area (usually the forearm or back) must be cleaned with alcohol before the extract is applied via a lancet device.

If an immunotherapy dose is missed, contact your allergist. Do not double the next dose, as this increases the risk of a systemic reaction.

Signs of overdose (strychnine poisoning) include extreme muscle stiffness, painful convulsions (triggered by light or sound), and difficulty breathing. This is a medical emergency. Immediate treatment involves airway management, benzodiazepines for seizures, and a quiet environment.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not attempt to use raw nux-vomica seeds, as they are potentially lethal.

When used as an allergenic extract, the most common reactions are localized to the site of administration:

• Wheal and Flare: A raised, red, itchy bump at the test site (this is the intended diagnostic response).
• Local Pruritus: Intense itching at the injection or prick site.
• Erythema: Redness of the skin surrounding the application area.

• Subcutaneous Swelling: Large local reactions that may persist for 24-48 hours.
• Mild Headache: A transient dull ache following exposure.
• Nausea: Slight gastrointestinal upset, particularly in sensitive individuals.

• Systemic Urticaria: Hives appearing on parts of the body away from the test site.
• Dizziness: A feeling of lightheadedness or vertigo.
• Mild Bronchospasm: Slight wheezing or chest tightness.

> Warning: Stop the procedure and call for emergency help if you experience any of the following:

• Anaphylaxis: A life-threatening allergic reaction characterized by throat swelling, rapid pulse, and a sharp drop in blood pressure.
• Seizures or Convulsions: Involuntary muscle contractions or stiffening, indicating systemic alkaloid toxicity.
• Risus Sardonicus: A characteristic abnormal, sustained spasm of the facial muscles that appears to produce grinning.
• Dyspnea: Severe difficulty breathing or gasping for air.

Prolonged exposure to low levels of nux-vomica alkaloids can lead to increased reflex excitability and chronic sleep disturbances. There is no evidence of carcinogenic potential in humans at diagnostic doses.

Warning: Risk of Severe Toxicity and Anaphylaxis

Strychnos Nux-vomica Seed contains strychnine, a potent neurotoxin. Systemic absorption can lead to fatal convulsions and respiratory failure. Additionally, as an allergenic extract, this product can cause severe, life-threatening anaphylactic reactions. It must only be administered by healthcare professionals trained in emergency resuscitation.

Report any unusual symptoms to your healthcare provider immediately.

Strychnos Nux-vomica Seed is a substance with a high potential for toxicity. It must never be used as a dietary supplement in its raw form. All clinical use must be supervised by an allergist or immunologist. Patients with a history of seizures or neurological disorders are at a significantly higher risk.

No official FDA black box warning exists for the allergenic extract specifically, but clinical literature and the CDC emphasize the extreme lethality of the strychnine component found in the seed. Fatalities have been reported with as little as 30-100 mg of ingested strychnine.

• Anaphylaxis Risk: Like all allergenic extracts, there is a risk of sudden, severe allergic reactions. Patients should remain in the clinic for at least 30 minutes after administration.
• Neurotoxicity: Due to the glycine-antagonist properties of its alkaloids, it may lower the seizure threshold.
• Cardiovascular Stress: The excitatory effects of the alkaloids can increase heart rate and blood pressure, posing a risk to patients with unstable angina or severe hypertension.

• Observation: Continuous monitoring for 30 minutes post-administration for signs of systemic reaction.
• Neurological Assessment: Baseline assessment of reflexes if systemic immunotherapy is planned.
• Lung Function: Peak flow or spirometry may be required for patients with asthma before testing.

Patients should avoid driving or operating heavy machinery for at least 1 hour after receiving an allergenic extract, as dizziness or systemic reactions can impair reaction times.

Alcohol should be avoided on the day of testing or treatment. Alcohol can mask the symptoms of a systemic reaction and may theoretically potentiate the CNS effects of nux-vomica alkaloids.

If a patient experiences a systemic reaction (Grade 2 or higher), the use of the extract must be discontinued or the dose significantly reduced. There is no withdrawal syndrome associated with discontinuing allergenic extracts.

> Important: Discuss all your medical conditions, especially neurological or heart issues, with your healthcare provider before starting Strychnos Nux-vomica Seed.

• CNS Stimulants (e.g., Amphetamines, Cocaine): Combining these with nux-vomica alkaloids can lead to extreme CNS overstimulation, potentially causing fatal seizures.
• Glycine Antagonists: Any other substance that interferes with glycine signaling will have a synergistic toxic effect.

• Beta-Blockers: These may interfere with the effectiveness of epinephrine if it is needed to treat an anaphylactic reaction caused by the extract.
• MAO Inhibitors: May potentiate the hypertensive effects of the alkaloids.
• Antipsychotics: Some antipsychotics lower the seizure threshold, increasing the risk of convulsions if the extract is absorbed systemically.

• Theophylline: May increase the risk of tachycardia and CNS excitation.
• Selective Serotonin Reuptake Inhibitors (SSRIs): Potential for increased tremor or jitteriness.

• Caffeine: High doses of caffeine can worsen the excitatory effects of the alkaloids, leading to increased heart rate and anxiety.
• High-Fat Meals: May delay the absorption of any incidentally ingested alkaloids but does not reduce the ultimate toxicity.

• Ephedra/Ma Huang: Significantly increases the risk of cardiovascular events and seizures.
• St. John's Wort: May alter the hepatic metabolism (CYP3A4/2B6) of the alkaloids, though the clinical significance is unclear.

Strychnos Nux-vomica Seed does not typically interfere with standard blood chemistry or hematology tests. However, it will produce a positive result on specific skin tests for plant allergens.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those affecting the nervous system.

• Hypersensitivity: Known severe allergy to any component of the Strychnos genus.
• Seizure Disorders: Patients with epilepsy or a history of status epilepticus should not be exposed to nux-vomica alkaloids due to the risk of triggering convulsions.
• Recent Myocardial Infarction: The potential for CNS-mediated cardiovascular stress makes use unsafe in the acute post-MI period.
• Pregnancy: Due to the potent neurotoxic effects of strychnine, it is absolutely contraindicated.

• Severe Asthma: Patients with poorly controlled asthma are at a much higher risk of fatal anaphylaxis during allergenic testing.
• Beta-Blocker Therapy: While not an absolute contraindication, it complicates the treatment of potential allergic reactions.
• Hepatic Cirrhosis: Reduced ability to detoxify alkaloids increases the risk of systemic effects.

Patients allergic to other members of the Loganiaceae family may exhibit cross-reactivity to Strychnos Nux-vomica Seed extracts.

> Important: Your healthcare provider will evaluate your complete medical history, including neurological health, before prescribing this extract.

FDA Pregnancy Category X (Estimated). Strychnos Nux-vomica Seed is contraindicated in pregnancy. Strychnine readily crosses the placental barrier and is highly fetotoxic. It can cause uterine contractions and fetal neurological damage. It should never be used in women who are or may become pregnant.

Alkaloids from the seed, including strychnine, are excreted into breast milk. Due to the high sensitivity of the infant nervous system to glycine-receptor antagonists, breastfeeding is not recommended if the mother is being treated with non-homeopathic forms of this extract.

Safety and effectiveness in the pediatric population have not been established. Use in children is generally discouraged due to the risk of accidental systemic absorption and the severe nature of strychnine toxicity in smaller body masses.

Elderly patients should be monitored for increased sensitivity to CNS stimulants. Age-related declines in renal and hepatic function may necessitate lower doses in immunotherapy protocols to prevent accumulation.

In patients with a GFR < 60 mL/min, the clearance of strychnine metabolites is reduced. While diagnostic skin testing is generally safe, systemic immunotherapy requires cautious dose titration.

Child-Pugh Class B and C patients should avoid exposure to this extract. The liver is the primary site of alkaloid detoxification; impaired function significantly increases the half-life and toxicity of the substance.

> Important: Special populations require individualized medical assessment and often a consultation with a toxicologist or high-risk specialist.

Strychnos Nux-vomica Seed contains the indole alkaloids strychnine and brucine. Strychnine is a potent, selective antagonist of the inhibitory neurotransmitter glycine. It binds to the alpha-1 subunit of the glycine receptor in the spinal cord and brainstem. By preventing glycine from binding, it removes the normal inhibitory control over motor neurons, leading to unchecked reflex stimulation and tetanic convulsions.

• Onset of Action: 15–30 minutes (oral/systemic); 5–15 minutes (skin prick).
• Duration of Effect: 12–24 hours for systemic neurological effects.
• Dose-Response: There is a very steep dose-response curve; small increases in dose can lead to a rapid transition from therapeutic (allergenic) response to lethal toxicity.

| Parameter | Value |

|---|---|

| Bioavailability | >80% (Oral/Systemic) |

| Protein Binding | ~25% |

| Half-life | 10-12 hours |

| Tmax | 1-2 hours |

| Metabolism | Hepatic (CYP2B6) |

| Excretion | Renal (15% unchanged) |

• Molecular Formula (Strychnine): C21H22N2O2
• Molecular Weight: 334.41 g/mol
• Solubility: Slightly soluble in water; soluble in ethanol and chloroform.
• Structure: A complex heptacyclic indole alkaloid.

Strychnos Nux-vomica Seed is classified as a Non-Standardized Plant Allergenic Extract [EPC]. It is related to other allergenic extracts used in diagnostic immunology, though it is unique due to its specific toxicological profile.